Cancer

Matt's Take Matthew Herper

New data show the HPV vaccine prevents cancer in men, too. Why don’t more people get it?

Adam's Take Adam Feuerstein

STAT Plus: Setting the table: What to expect at this year’s ASCO meeting

Biotech Andrew Joseph

STAT Plus: At a flashy new research hub, AstraZeneca lays out ambitious growth goals

In the Lab Angus Chen

Black Americans’ risk for breast cancer gains clarity in analysis of 40,000 genomes

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: PDS Biotech’s survival benefit is absurdly overstated

Biotech Andrew Joseph

STAT Plus: Galapagos, in makeover mode, strikes deal to make CAR-T therapies at blood centers across U.S.

The Readout Elaine Chen

STAT Plus: Leqembi gets closer to being offered as an injection

Pharmalot Ed Silverman

STAT Plus: Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug

Health Nicholas Florko

After decades fighting Big Tobacco, Cliff Douglas now leads a foundation funded by his former adversaries

First Opinion Patrick Skerrett

First Opinion essay on colorectal cancer screening: letter and response

Biotech Jonathan Wosen

STAT Plus: Exact Sciences’ stock tumbles amid worries cancer detection firm’s growth may slow

Pharmalot Ed Silverman

STAT Plus: A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available

In the Lab Nicholas St. Fleur

Q&A: Meet the scientist sending tumors into space

Letters to the editor Patrick Skerrett

Readers respond to funding academic medical centers, the ‘residency research arms race,’ and more

First Opinion Barron H. Lerner

Why isn’t there agreement on when women need to start getting mammograms?

Biotech Elaine Chen

STAT Plus: BridgeBio spins out oncology company as it focuses on heart drug

Biotech Allison DeAngelis

STAT Plus: Novartis extends radiopharma plans with $1 billion acquisition

In the Lab Angus Chen

STAT Plus: Biological clocks could be the key to longer, healthier lives. But scientists don’t yet agree on what ‘aging’ is

First Opinion Simone Ledward-Boseman

Colorectal cancer is increasing among young people. It’s time to boost research on it

Health Angus Chen

With younger women getting breast cancer, national panel lowers mammogram screening age to 40

The Readout Meghana Keshavan

STAT Plus: House bill aimed at Chinese biotechs is advancing 

Biotech Adam Feuerstein

STAT Plus: Ono Pharmaceutical to acquire Deciphera Pharma, maker of cancer drugs, for $2.4 billion

Exclusive Adam Feuerstein

STAT Plus: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition

Letters to the editor Patrick Skerrett

STAT readers respond to First Opinion essays on site-neutral payments, free medical school tuition, and more

The Readout Elaine Chen

STAT Plus: A spending frenzy on obesity drugs

First Opinion Folasade P. May

Balancing hope and reality: The promise and peril of blood-based colorectal cancer screening

Biotech Jason Mast

STAT Plus: Day One drug for common childhood brain tumor approved by FDA

First Opinion Peter J. Pitts and Timothy R. Franson

Bashing accelerated approval isn’t supported by the data

In the Lab Angus Chen

STAT Plus: Dana-Farber retracts string of studies in systematic review of data integrity